Key result
Adipose tissue dysfunction and inflammation drive cardiometabolic risk in obesity more than total fat mass.
Why the study?
The pathophysiology of obesity involves complex mechanisms beyond caloric imbalance, including adipose tissue dysfunction, chronic inflammation, and insulin resistance contributing to cardiometabolic disease.
This review provides an integrated framework demonstrating that cardiometabolic risk in obesity is driven by adipose tissue dysfunction and chronic inflammation, highlighting the need for metabolic and tissue-specific assessments beyond simple body mass index.
May refine cardiometabolic risk assessment beyond BMI in obesity; extends mechanistic synthesis but leaves prospective validation open.
Obesity has reached epidemic proportions worldwide, affecting approximately 890 million adults as of 2022, and projections indicate the number will exceed 1.5 billion by 2035. While excess body weight is frequently framed as a simple imbalance between caloric intake and expenditure, the pathophysiology of obesity is considerably more complex, involving adipose tissue dysfunction, chronic low-grade inflammation, disrupted adipokine secretion, and progressive insulin resistance. This narrative-analytical review synthesizes current evidence on the molecular and systemic mechanisms through which dysfunctional adipose tissue, particularly visceral fat, drives cardiometabolic disease. The review examines adipocyte hypertrophy and extracellular matrix remodeling, ectopic lipid deposition, leptin and adiponectin dysregulation, macrophage polarization and inflammatory signaling through NF-kB, JNK, and the NLRP3 inflammasome, mitochondrial dysfunction, and the emerging phenotype of sarcopenic obesity. Synthesizing data from systematic reviews, prospective cohort studies, and clinical metabolic research published between 2020 and 2026, the review proposes an integrated clinical framework that moves beyond body weight as a primary treatment target toward metabolic health, tissue composition, and functional outcomes. Findings are relevant to internists, endocrinologists, cardiologists, and preventive medicine practitioners.
No takes yet. Share an insight, caveat, or question.
Mariia Hataliak (2026) conducted a review in Obesity and Cardiometabolic Disease. Adipose tissue dysfunction and obesity vs. Healthy metabolic function / normal weight was evaluated. Adipose tissue dysfunction, chronic inflammation, and insulin resistance, rather than total fat mass alone, are the primary biological drivers of cardiometabolic risk in obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: